Skip to content
Triangle logo TriangleGet started
← Study library

NCT01505699 · CITED IN SOURCE DOCUMENTS

Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
Not reported
Status at capture
COMPLETED
Registry last update
2017-05-17

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: * Samples from patients enrolled on ECOG-2993 * Samples from patients with recurrent cytogenetic abnormalities other than BCR-ABL, including MLL/AF4, E2A/PBX1, and TEL/AML1 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
healthy Volunteers
false
maximum Age
65 Years
minimum Age
15 Years
sampling Method
NON_PROBABILITY_SAMPLE
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
study Population
Samples from patients enrolled on E2993 who provided samples for research
Treatment arms and interventions
interventions
  1. name
    RNA analysis
    type
    GENETIC
  2. name
    cytogenetic analysis
    type
    GENETIC
  3. name
    microarray analysis
    type
    GENETIC
  4. name
    laboratory biomarker analysis
    type
    OTHER
Study design
observational Model
OTHER
time Perspective
RETROSPECTIVE
Enrollment
count
186
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Comprehensive view of microRNA expression by cytogenetic subgroup
    time Frame
    1 year
  2. measure
    MicroRNA expression in relation to clinical outcome
    time Frame
    1 year
  3. measure
    Differential microRNA expression between normal B-cells and progenitors compared to B-ALL
    time Frame
    1 year
Full study description
brief Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.
detailed Description
OBJECTIVES: * To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo. * To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups. OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-db97f714421cae5c825c
      requested nct id
      NCT01505699
      primary nct id
      NCT01505699
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      e697833d4abd9767a7115cba8c1fed98c52a5419a6e33d78e513248f19638e90
      payload sha256
      6d235dae4fbdf9776cb961c5eb39c9719329e793ab206f942ff1b5d32d793ec8
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-db97f714421cae5c825c
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT01505699
      occurrences
      1. context exact
        ts with high-risk or Ph-positive ALL.[<a href="#cit/section_6.14">14</a>-<a href="#cit/section_6.17">17</a>] This was confirmed in the <a href="/clinicaltrials/NCT01505699">ECOG-2993</a> study (NCT01505699).[<a href="#cit/section_6.7">7</a>]<div class="pdq-content-list"><ul id="_211"><li>The use of allogeneic BMT as primary conso
        end
        85589
        exact text
        NCT01505699
        start
        85578
      2. context exact
        LL.[<a href="#cit/section_6.14">14</a>-<a href="#cit/section_6.17">17</a>] This was confirmed in the <a href="/clinicaltrials/NCT01505699">ECOG-2993</a> study (NCT01505699).[<a href="#cit/section_6.7">7</a>]<div class="pdq-content-list"><ul id="_211"><li>The use of allogeneic BMT as primary consolidation therapy is limited by bot
        end
        85623
        exact text
        NCT01505699
        start
        85612
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/aaea50b1739b09793b.html
      source file sha256
      e697833d4abd9767a7115cba8c1fed98c52a5419a6e33d78e513248f19638e90
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:52.892398+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      3a5c5d02f311c019ea1c519cd09c38b3341949b5c01111d75e3b012b6e87d6d8
      source title
      Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: March 17, 2025
        datetime
        2025-03-17T12:00:00Z
        display
        March 17, 2025

    Preserved source evidence · Not medical advice